Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Towards an off-grid fecal sludge treatment unit: demonstrating energy positive thermal treatment.

Myers T, Schoebitz L, Woolley S, Sanchez Ferragut J, Thostenson J, Jooss K, Piascik J, Frechette A, Hotz N, Stoner BR, Hallowell J.

Gates Open Res. 2019 Apr 10;3:1176. doi: 10.12688/gatesopenres.12929.1. eCollection 2019.

2.

Heart-cut nano-LC-CZE-MS for the characterization of proteins on the intact level.

Jooß K, Scholz N, Meixner J, Neusüß C.

Electrophoresis. 2019 Apr;40(7):1061-1065. doi: 10.1002/elps.201800411. Epub 2019 Jan 4.

PMID:
30575976
3.

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R.

Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. [Epub ahead of print]

PMID:
30556813
4.

Capillary zone electrophoresis coupled to drift tube ion mobility-mass spectrometry for the analysis of native and APTS-labeled N-glycans.

Jooß K, Meckelmann SW, Klein J, Schmitz OJ, Neusüß C.

Anal Bioanal Chem. 2019 Sep;411(24):6255-6264. doi: 10.1007/s00216-018-1515-7. Epub 2018 Dec 10.

PMID:
30535529
5.

Recent advances in capillary electrophoresis-mass spectrometry: Instrumentation, methodology and applications.

Stolz A, Jooß K, Höcker O, Römer J, Schlecht J, Neusüß C.

Electrophoresis. 2019 Jan;40(1):79-112. doi: 10.1002/elps.201800331. Epub 2018 Nov 12. Review.

PMID:
30260009
6.

Two-dimensional capillary electrophoresis-mass spectrometry (CE-CE-MS): coupling MS-interfering capillary electromigration methods with mass spectrometry.

Schlecht J, Jooß K, Neusüß C.

Anal Bioanal Chem. 2018 Oct;410(25):6353-6359. doi: 10.1007/s00216-018-1157-9. Epub 2018 Jun 4. Review.

PMID:
29862434
7.

Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Lee CH, Yelensky R, Jooss K, Chan TA.

Trends Immunol. 2018 Jul;39(7):536-548. doi: 10.1016/j.it.2018.04.005. Epub 2018 May 8. Review.

PMID:
29751996
8.

Two-dimensional capillary zone electrophoresis-mass spectrometry for the characterization of intact monoclonal antibody charge variants, including deamidation products.

Jooß K, Hühner J, Kiessig S, Moritz B, Neusüß C.

Anal Bioanal Chem. 2017 Oct;409(26):6057-6067. doi: 10.1007/s00216-017-0542-0. Epub 2017 Aug 12.

PMID:
28801824
9.

Raman spectroscopy and capillary zone electrophoresis for the analysis of degradation processes in commercial effervescent tablets containing acetylsalicylic acid and ascorbic acid.

Neuberger S, Jooß K, Flottmann D, Scriba G, Neusüß C.

J Pharm Biomed Anal. 2017 Feb 5;134:122-129. doi: 10.1016/j.jpba.2016.11.020. Epub 2016 Nov 15.

PMID:
27907854
10.

Interference-free mass spectrometric detection of capillary isoelectric focused proteins, including charge variants of a model monoclonal antibody.

Hühner J, Jooß K, Neusüß C.

Electrophoresis. 2017 Mar;38(6):914-921. doi: 10.1002/elps.201600457. Epub 2016 Dec 22.

PMID:
27885684
11.

Quantification of ascorbic acid and acetylsalicylic acid in effervescent tablets by CZE-UV and identification of related degradation products by heart-cut CZE-CZE-MS.

Neuberger S, Jooß K, Ressel C, Neusüß C.

Anal Bioanal Chem. 2016 Dec;408(30):8701-8712. Epub 2016 Jul 12.

PMID:
27405873
12.

Reproducibility and quantification of illicit drugs using matrix-assisted ionization (MAI) mass spectrometry.

Chakrabarty S, DeLeeuw JL, Woodall DW, Jooss K, Narayan SB, Trimpin S.

Anal Chem. 2015 Aug 18;87(16):8301-6. doi: 10.1021/acs.analchem.5b01436. Epub 2015 Aug 4.

PMID:
26186653
13.

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.

J Immunother Cancer. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3. eCollection 2014.

14.

In-line SPE-CE using a fritless bead string design--application for the analysis of organic sulfonates including inline SPE-CE-MS for APTS-labeled glycans.

Jooß K, Sommer J, Bunz SC, Neusüß C.

Electrophoresis. 2014 May;35(9):1236-43. doi: 10.1002/elps.201300388. Epub 2013 Dec 9.

PMID:
24170563
15.

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models.

Palsson S, Hickling TP, Bradshaw-Pierce EL, Zager M, Jooss K, O'Brien PJ, Spilker ME, Palsson BO, Vicini P.

BMC Syst Biol. 2013 Sep 28;7:95. doi: 10.1186/1752-0509-7-95.

16.

Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy.

Liang SC, Moskalenko M, Van Roey M, Jooss K.

Clin Immunol. 2013 Aug;148(2):287-98. doi: 10.1016/j.clim.2013.05.011. Epub 2013 May 25.

PMID:
23811319
17.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.

PMID:
22878899
18.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
19.

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.

Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, Jooss KU, Harding TC.

Cancer Immunol Immunother. 2010 Sep;59(9):1313-23. doi: 10.1007/s00262-010-0858-5. Epub 2010 May 25.

PMID:
20499060
20.

Combination of the 2A/furin technology with an animal component free cell line development platform process.

Jostock T, Dragic Z, Fang J, Jooss K, Wilms B, Knopf HP.

Appl Microbiol Biotechnol. 2010 Jul;87(4):1517-24. doi: 10.1007/s00253-010-2625-0. Epub 2010 May 12.

PMID:
20461511
21.

Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.

Li B, Simmons A, Du T, Lin C, Moskalenko M, Gonzalez-Edick M, VanRoey M, Jooss K.

Clin Immunol. 2009 Nov;133(2):184-97. doi: 10.1016/j.clim.2009.07.008. Epub 2009 Aug 7.

PMID:
19664962
22.

Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.

Ganesh S, Gonzalez-Edick M, Gibbons D, Waugh J, Van Roey M, Jooss K.

Hum Gene Ther. 2009 Oct;20(10):1201-13. doi: 10.1089/hum.2009.045.

PMID:
19572803
23.

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.

Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.

Clin Cancer Res. 2009 Mar 1;15(5):1623-34. doi: 10.1158/1078-0432.CCR-08-1825. Epub 2009 Feb 10.

24.

Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Robinson M, Li B, Ge Y, Ko D, Yendluri S, Harding T, VanRoey M, Spindler KR, Jooss K.

J Virol. 2009 Apr;83(8):3450-62. doi: 10.1128/JVI.02561-08. Epub 2009 Feb 4.

25.

Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.

Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, Jooss K.

Cancer Gene Ther. 2009 May;16(5):383-92. doi: 10.1038/cgt.2008.90. Epub 2008 Nov 14.

PMID:
19011598
26.

Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.

Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K.

Clin Cancer Res. 2008 Jun 15;14(12):3933-41. doi: 10.1158/1078-0432.CCR-07-4732.

27.

Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.

Li B, VanRoey M, Triebel F, Jooss K.

Clin Cancer Res. 2008 Jun 1;14(11):3545-54. doi: 10.1158/1078-0432.CCR-07-5200.

28.

Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.

Lin JM, Li B, Rimmer E, VanRoey M, Jooss K.

Exp Hematol. 2008 Mar;36(3):319-28. doi: 10.1016/j.exphem.2007.11.005.

PMID:
18279719
29.

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity.

Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K.

Cancer Immunol Immunother. 2008 Aug;57(8):1263-70. doi: 10.1007/s00262-008-0451-3. Epub 2008 Jan 31.

PMID:
18236040
30.

Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.

Robinson M, Ge Y, Ko D, Yendluri S, Laflamme G, Hawkins L, Jooss K.

Cancer Gene Ther. 2008 Jan;15(1):9-17. Epub 2007 Sep 14.

PMID:
17853920
31.

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K.

Clin Immunol. 2007 Oct;125(1):76-87. Epub 2007 Aug 13.

PMID:
17706463
32.

Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.

Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M, Yun CO, Jooss K.

Cancer Res. 2007 May 1;67(9):4399-407. Erratum in: Cancer Res. 2007 Jun 15;67(12):5998.

33.

GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.

Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K.

Cancer Immunol Immunother. 2007 Oct;56(10):1653-65. Epub 2007 Apr 5.

PMID:
17410360
34.

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

Fang J, Yi S, Simmons A, Tu GH, Nguyen M, Harding TC, VanRoey M, Jooss K.

Mol Ther. 2007 Jun;15(6):1153-9. Epub 2007 Mar 20.

35.

Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.

Li B, VanRoey MJ, Jooss K.

Clin Immunol. 2007 May;123(2):155-65. Epub 2007 Feb 22.

PMID:
17320482
36.

Rapamycin-regulated control of antiangiogenic tumor therapy following rAAV-mediated gene transfer.

Nguyen M, Huan-Tu G, Gonzalez-Edick M, Rivera VM, Clackson T, Jooss KU, Harding TC.

Mol Ther. 2007 May;15(5):912-20. Epub 2007 Jan 23.

37.

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

Hege KM, Jooss K, Pardoll D.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):321-52. Review.

PMID:
17169779
38.

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.

Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K.

Clin Cancer Res. 2006 Nov 15;12(22):6808-16.

39.

Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors.

Harding TC, Dickinson PJ, Roberts BN, Yendluri S, Gonzalez-Edick M, Lecouteur RA, Jooss KU.

Hum Gene Ther. 2006 Aug;17(8):807-20.

PMID:
16942441
40.

Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma.

Chu Y, Wang LX, Yang G, Ross HJ, Urba WJ, Prell R, Jooss K, Xiong S, Hu HM.

J Immunother. 2006 Jul-Aug;29(4):367-80.

PMID:
16799332
41.

AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma.

Harding TC, Lalani AS, Roberts BN, Yendluri S, Luan B, Koprivnikar KE, Gonzalez-Edick M, Huan-Tu G, Musterer R, VanRoey MJ, Ozawa T, LeCouter RA, Deen D, Dickinson PJ, Jooss K.

Mol Ther. 2006 May;13(5):956-66. Epub 2006 Mar 31.

42.

The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.

Prell RA, Gearin L, Simmons A, Vanroey M, Jooss K.

Cancer Immunol Immunother. 2006 Oct;55(10):1285-93. Epub 2006 Jan 12.

PMID:
16408214
43.

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.

Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K.

Cancer Res. 2005 Aug 1;65(15):6901-9.

44.

Rapid generation of high-level antibodies in vitro and in vivo.

Fang J, Jooss K.

Discov Med. 2005 Aug;5(28):367-70.

45.

Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.

He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K.

Cancer Res. 2005 Jun 1;65(11):4739-46.

46.

Stable antibody expression at therapeutic levels using the 2A peptide.

Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K.

Nat Biotechnol. 2005 May;23(5):584-90. Epub 2005 Apr 17.

PMID:
15834403
47.
48.

Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy.

Lalani AS, Chang B, Lin J, Case SS, Luan B, Wu-Prior WW, VanRoey M, Jooss K.

Mol Ther. 2004 Jan;9(1):56-66.

49.

Human immunodeficiency virus-1 Nef expression induces intracellular accumulation of multivesicular bodies and major histocompatibility complex class II complexes: potential role of phosphatidylinositol 3-kinase.

Stumptner-Cuvelette P, Jouve M, Helft J, Dugast M, Glouzman AS, Jooss K, Raposo G, Benaroch P.

Mol Biol Cell. 2003 Dec;14(12):4857-70. Epub 2003 Sep 17.

50.

Safety of adeno-associated virus gene therapy vectors: a current evaluation.

Monahan PE, Jooss K, Sands MS.

Expert Opin Drug Saf. 2002 May;1(1):79-91. Review.

PMID:
12904163

Supplemental Content

Support Center